Nanotechnology Now - News Story: Senesco Technologies Reports On Results Of Preclinical Multiple Myeloma Studies

Home > News > Senesco Technologies Reports On Results Of Preclinical Multiple Myeloma Studies

February 7th, 2008

Senesco Technologies Reports On Results Of Preclinical Multiple Myeloma Studies

Abstract:
Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced the results of preclinical animal studies focused on multiple myeloma that were conducted concurrently at Mayo Clinic and the University of Waterloo. The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco's Factor 5A technology to induce apoptosis in tumors. Additionally, the studies evaluated the efficacy of nanoparticles as a vehicle for encapsulation and delivery of Factor 5A to tumors.

SCID (severe combined immunodeficiency) mice were injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were injected intratumorally with Factor 5A therapy encapsulated in nanoparticles, while control mice received a nanoparticle without the Factor 5A therapy. One of the dosing regimens showed evidence of significant tumor regression relative to the untreated control mice, while the other showed a diminished rate of tumor growth along with some regression.

Source:
medicalnewstoday.com

Bookmark: